Showing results (441-450 of 513) with videos related to

Sort By:
Pageof 52
Annals of the Rheumatic Diseases|October 7, 2021
Does biologic therapy impact the development of PsA among patients with psoriasis?Elana Meer, Joseph F Merola, Robert Fitzsimmons, et al.
Lancet (London, England)|February 7, 2021
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trialKristian Reich, Kim A Papp, Andrew Blauvelt, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 11, 2026
Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of the Phase 3, Randomized, Placebo-Controlled SOLSTICE StudyAlexis Ogdie, Joseph F Merola, Philip J Mease, et al.
Rheumatology and Therapy|November 14, 2025
On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor InhibitorsPhilip J Mease, Jessica A Walsh, Timothy P Fitzgerald, et al.
Advances in Therapy|November 21, 2025
Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A InhibitorsPhilip J Mease, Jessica A Walsh, Timothy P Fitzgerald, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 25, 2026
Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From the Phase 2a, Multicenter, Randomized, Double-Blind, Proof-of-Concept AFFINITY StudyJose U Scher, Iain B McInnes, Enrique R Soriano, et al.
BMC Rheumatology|May 21, 2024
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled studyAlexis Ogdie, Joseph F Merola, Philip J Mease, et al.
Applied Clinical Informatics|June 1, 2017
The effects of natural language processing on cross-institutional portability of influenza case detection for disease surveillanceJeffrey P Ferraro, Ye Ye, Per H Gesteland, et al.
Langmuir : the ACS Journal of Surfaces and Colloids|December 10, 2013
Spontaneous assembly of carbon-based chains in polymer matrixes through surface charge templatesO Gennari, S Grilli, S Coppola, et al.
Annals of Surgery|August 11, 2020
Portable Automated Surveillance of Surgical Site Infections Using Natural Language Processing: Development and ValidationBrian T Bucher, Jianlin Shi, Jeffrey P Ferraro, et al.
Pageof 52